Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Global survey reveals major variation in the measurement of bone and mineral metabolism biomarkers (opens in a new tab)

medicalxpress.com · 2026-09-29

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

One claim goes further than the study.

  • 4 supported
  • 1 overstated

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

One claim overstates the study. Four of five check out.

  • 4 supported
  • 1 overstated
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5OverstatedPublished Aug. 7, 2026, in Clinical Chemistry and Laboratory Medicine, the study collected 231 responses from 41 countries and found substantial variation in global BSI laboratory practices that limits data sharing, test standardization and clinical impact.View evidenceHide evidence

As stated231 responses from 41 countries

Why this verdict

The 231 responses and 41 countries are supported, as is the finding of marked heterogeneity in BSI laboratory practices. However, the claim that the study found variation that ‘limits data sharing, test standardization and clinical impact’ is stronger than the abstract-level evidence summarized here, which documents descriptive heterogeneity and discusses needs for harmonization and improved comparability/interpretation rather than demonstrating downstream limits on data sharing or clinical impact. The publication date and journal are not verifiable from the supplied abstract profile.

1

Study evidence

Respondents reported marked heterogeneity in analytical platforms, specimen types, reporting units, and reference intervals/clinical decision thresholds for BSIs, including variability among laboratories using the same manufacturer/instrument.

“we conducted an international descriptive survey of BSI practices”
Claim 2 of 5SupportedResearchers from the International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Joint Committee on Bone Metabolism published a study examining self-reported practices among laboratories that measure bone status indices in blood tests.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that the paper is an international cross-sectional web-based questionnaire survey of laboratory professionals about BSI laboratory practices, including assay availability, specimen types, platforms, EQA, reference intervals/thresholds, reporting units, interpretation, and reimbursement. The IOF/IFCC context is consistent with the profile’s description of recruitment through IFCC/IOF networks, though the detailed author/committee affiliation is not independently appraised beyond the supplied profile.

1

Study evidence

Respondents reported marked heterogeneity in analytical platforms, specimen types, reporting units, and reference intervals/clinical decision thresholds for BSIs, including variability among laboratories using the same manufacturer/instrument.

“we conducted an international descriptive survey of BSI practices”
Claim 3 of 5SupportedResearchers observed substantial differences across laboratories in analytical platforms and instruments, specimen types, reporting units, reference intervals and decision thresholds, external quality assessment participation, and reimbursement practices.View evidenceHide evidence

Why this verdict

The profile directly reports marked heterogeneity across analytical platforms, specimen types, reporting units, reference intervals/decision thresholds, EQA participation, assay availability, and reimbursement practices.

1

Study evidence

Respondents reported marked heterogeneity in analytical platforms, specimen types, reporting units, and reference intervals/clinical decision thresholds for BSIs, including variability among laboratories using the same manufacturer/instrument.

“we conducted an international descriptive survey of BSI practices”
2

Study evidence

Reference intervals for BSIs showed considerable variability, including substantial variation among laboratories using the same manufacturer and instrument.

“Reference intervals varied considerably, even among laboratories using the same manufacturer and instrument.”
Claim 4 of 5SupportedReference intervals varied considerably, even among laboratories using the same manufacturer and instrument, and EQA participation was high for total alkaline phosphatase and parathyroid hormone but substantially lower for β-CTX-I and PINP.View evidenceHide evidence

Why this verdict

The profile specifically states that reference intervals varied considerably even among laboratories using the same manufacturer and instrument, and that EQA participation was high for total ALP and PTH but lower for β-CTX-I and PINP.

1

Study evidence

Reference intervals for BSIs showed considerable variability, including substantial variation among laboratories using the same manufacturer and instrument.

“Reference intervals varied considerably, even among laboratories using the same manufacturer and instrument.”
Claim 5 of 5SupportedThe article says adoption of β-CTX-I and PINP testing seemed incomplete, access to bone-specific ALP and TRAP5b remains limited, PTH testing showed poor harmonization because second- and third-generation assays are used concurrently, vitamin D decision thresholds varied widely, and inappropriate ordering of 1,25(OH)2D instead of 25(OH)D was frequently reported.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the listed specific findings: incomplete β-CTX-I and PINP adoption, limited access to bone-specific ALP and TRAP5b, poor PTH harmonization due to concurrent second- and third-generation assays, widely variable vitamin D thresholds, and frequent perceived misordering of 1,25(OH)2D instead of 25(OH)D. The story’s wording is broadly consistent, especially because it frames adoption as seeming incomplete and mentions the self-reported nature of the data, although the paper profile’s wording is more explicitly about perceived misordering.

1

Study evidence

Reference intervals for BSIs showed considerable variability, including substantial variation among laboratories using the same manufacturer and instrument.

“Reference intervals varied considerably, even among laboratories using the same manufacturer and instrument.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Convenience/network recruitment through IFCC/IOF and professional networks may introduce selection bias and limit representativeness of all global laboratories.

    The supplied caveats mention self-reporting but do not mention convenience/network sampling, selection bias, or limited representativeness, which is an interpretation-changing limitation for a global practice survey.

    From Cross-sectional web-based questionnaire survey (convenience/network sampling)

  • Adoption of β-CTX-I and PINP was incomplete overall but higher among laboratories following osteoporosis patients.

    The story notes incomplete adoption but does not include the qualifying detail that adoption was higher among laboratories that follow osteoporosis patients.

    From Cross-sectional web-based questionnaire survey (convenience/network sampling); Cross-sectional web-based survey

4 things the story did carry across
  • International cross-sectional web-based survey of laboratory professionals on BSI practices, with 231 responses and geographic information from 41 countries.
  • Marked heterogeneity in analytical platforms, specimen types, reporting units, reference intervals/decision thresholds, EQA participation, assay availability, and reimbursement.
  • Specific harmonization gaps: reference interval variability even within the same manufacturer/instrument, lower EQA participation for β-CTX-I and PINP, incomplete β-CTX-I/PINP adoption, limited bone-specific ALP/TRAP5b access, parallel PTH assay generations, variable vitamin D thresholds, and perceived vitamin D misordering.
  • Findings are based on self-reported practices and perceptions, creating potential reporting bias.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataCharacterize global laboratory practices for bone status indices (BSIs) via an international cross-sectional survey, documenting heterogeneity in assays, specimen types, platforms, reporting units, reference intervals/decision thresholds, interpretation, EQA participation, and reimbursement.Cross-sectional web-based questionnaire survey (convenience/network sampling)Expand

In plain English

International cross-sectional web-based questionnaire of laboratory professionals (231 responses; 225 with geographic data from 41 countries across six continents) describing current laboratory practices for bone status indices (BSIs). The survey documented marked global heterogeneity across analytical platforms, specimen types, reporting units, reference intervals or clinical decision thresholds, external quality assessment (EQA) participation, assay availability, and reimbursement; higher adoption of certain markers among laboratories following osteoporosis patients; and specific issues such as poor PTH harmonization and variable vitamin D decision thresholds.

Key findings

  • Respondents reported marked heterogeneity in analytical platforms, specimen types, reporting units, and reference intervals/clinical decision thresholds for BSIs, including variability among laboratories using the same manufacturer/instrument.
  • EQA participation was high for total alkaline phosphatase (ALP) and parathyroid hormone (PTH) but lower for β-CTX-I and PINP.
“we conducted an international descriptive survey of BSI practices”
What this piece can’t prove
  • Cross-sectional, web-based survey using professional society/network outreach (convenience sampling) — potential for sampling bias and limited representativeness of all global laboratories.
  • Findings are based on self-reported laboratory practices and perceptions; responses may be subject to reporting bias.
  • Abstract provides descriptive results without detailed quantitative breakdowns or inferential analyses in the presented summary.
2secondary dataDescribe specific areas of poor harmonization or gaps (e.g., variability in reference intervals even within same manufacturer/instrument; lower EQA participation for β-CTX-I and PINP; incomplete adoption of β-CTX-I and PINP; limited access to bone-specific ALP and TRAP5b; parallel use of 2nd/3rd generation PTH assays; wide vitamin D thresholds; perceived misordering of 1,25(OH)2D vs 25(OH)D).Cross-sectional web-based surveyExpand

In plain English

From an international cross-sectional web-based survey (231 responses, 225 with geographic info from 41 countries), the authors report multiple specific gaps and poor harmonization in laboratory practices for bone status indices (BSIs), including wide variability in reference intervals, uneven EQA participation by analyte, incomplete uptake of key bone turnover markers, limited access to certain assays, parallel use of different PTH assay generations, and variable vitamin D decision thresholds with frequent perceived misordering of analytes.

Key findings

  • Reference intervals for BSIs showed considerable variability, including substantial variation among laboratories using the same manufacturer and instrument.
  • External quality assessment (EQA) participation was high for total alkaline phosphatase (ALP) and parathyroid hormone (PTH) but lower for β-CTX-I and procollagen type I N-propeptide (PINP).
“Reference intervals varied considerably, even among laboratories using the same manufacturer and instrument.”
What this piece can’t prove
  • Findings derive from a cross-sectional web-based survey distributed via IFCC/IOF and professional networks, which may introduce selection bias and limit representativeness of all clinical laboratories.
  • Survey results are descriptive and self-reported; the abstract does not present formal quantitative measures of uncertainty or inferential analyses.
  • Abstract does not provide detailed numeric results for many reported differences (e.g., exact EQA participation rates, magnitude of reference interval variability).
Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Candidate

Real-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.

Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026 · PubMed

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Clinical Laboratory Practice for Bone Turnover markers

Clinical Chemistry and Laboratory Medicine (CCLM) · 2017 · Crossref

Source (opens in a new tab)
CandidateOpen access

Influence of vitamin D supplementation on bone mineral content, bone turnover markers, and fracture risk in South African schoolchildren: multicenter double-blind randomized placebo-controlled trial (ViDiKids).

2024 · Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)
CandidateOpen access

Influence of vitamin D supplementation on bone mineral content, bone turnover markers and fracture risk in South African schoolchildren: multicentre double-blind randomised placebo-controlled trial (ViDiKids)

2023 · Europe PMC

Tessa (opens in a new tab)Source (opens in a new tab)

And 10 more candidates considered.